There are 1,665,000 cases of sepsis annually in the U.S. (H-CUP#122) with near 500,000 associated deaths, and currently, no FDA approved treatment. ARDS (acute respiratory distress syndrome) and sepsis are medical emergencies requiring intensive care and are fatal in 30-70% of cases. ARDS and sepsis are main causes of death in geriatric patients. They develop severe infection from bacteria producing deadly toxins. Enterobacteriaceae, Pseudomonas aeruginosa, Salmonella spp, and Staphylococcus aureus are largely at cause. These toxins drive the immune response to a deadly excess. They bind to platelets (PT), activating them to express a ligand for TREM1 (Triggering Receptor Expressed on Myeloid Cells 1), a potent activation receptor of macrophages (M?) and neutrophils. Multiple activated PT ligands bind to M?, overtrigger TREM1, hyperactivating M? to release large amounts of inflammatory mediators producing an excess of systemic inflammatory response (SIR). Active M? expressing TREM1 are characteristic of sepsis and ARDS. Over 450 scientific articles document the role of TREM1 in inflammation. BioPROVAR's scientists have discovered TREM1-sv, a natural splice variant competitive receptor of TREM1 found in the blood and regulating the TREM1-activation pathway (TAP). As an immune therapy with antibiotics (AT), TREM1-sv showed a strong efficacy to increase survival probability in mice with SIR from cecum-ligation puncture (CLP), improving survival from 0% (AT alone) to 67%. Per comparison, inhibiting the LPS-activation pathway with a peptide blocking the Toll-Like Receptor 4 had no significant effect on survival. Based on these data and current knowledge, BioPROVAR is developing BioTremvarTM to administer supplement of human recombinant (hu r) TREM1-sv with antibiotics to sepsis and ARDS patients to alleviate SIR and prevent death. The rationale is that by competing for the excess of TREM1 ligands, TREM1-sv regulates TAP by reducing the number of TREM1-ligand complexes that trigger activation, thwarting M? hyperactivation, hence maintaining an effective immune response. Our objective here is to gather the preclinical data needed for the IND-enabling work of GLP production and toxicology studies. We aim to optimize non-GLP production of hu rTREM1-sv with a system transferable to cGMP and perform analytical characterization of its structural identity. BioTremvar's broad therapeutic efficacy will be demonstrated as an immune therapy with antibiotics in animal models of CLP-induced SIR using different doses and regimens. Using a mouse and a Guinea pig (nonrodent) animal model, we will generate pharmacodynamic, pharmacokinetic, PK/PD relationship data, and calculate the half-life of BioTremvarTM. BioPROVAR owns the rights to TREM1-sv. Our long-term goal is to validate BioTremvarTM cGMP in solution for intravenous injection to treat sepsis and ARDS patients. It is vital to have a therapeutic broadly effective at suppressing the central mechanism sustaining these diseases. The use of BioTremvarTM to inhibit SIR in sepsis or ARDS is innovative, scientifically grounded, and will save many lives. Public Health Relevance Statement ARDS (acute respiratory distress syndrome) and sepsis are a main cause of death in geriatric patients. These patients develop a severe infection from bacteria that is often fatal because of the toxins they release which hyperactivate the immune response and lead to a deadly excess of inflammation (DEI) in the lungs causing ARDS or spreading to the entire body and known as sepsis. About 1,665,000 cases of sepsis are diagnosed annually in the U.S. with 500,000 associated deaths and currently, no FDA approved treatment. BioPROVAR is developing BioTremvarTM, a natural protein found in the blood that prevents and inhibits the DEI found in sepsis and ARDS patients and will save thousands of lives every year.
Project Terms: Elderly ; advanced age ; elders ; geriatric ; late life ; later life ; older adult ; older person ; senior citizen ; Animals ; inhibitor/antagonist ; inhibitor ; Antibiotics ; Antibiotic Agents ; Antibiotic Drugs ; Miscellaneous Antibiotic ; Antibodies ; Monoclonal Antibodies ; Clinical Treatment Moab ; mAbs ; Antigens ; immunogen ; Bacterial Infections ; bacteria infection ; bacterial disease ; Biological Assay ; Assay ; Bioassay ; Biologic Assays ; Blood ; Blood Reticuloendothelial System ; Blood Platelets ; Marrow platelet ; Platelets ; Thrombocytes ; Cause of Death ; Cells ; Cell Body ; Cessation of life ; Death ; Diagnosis ; Disease ; Disorder ; Enterobacteriaceae ; Coliform Bacilli ; Enteric Bacteria ; Enterobacteria ; Enzyme-Linked Immunosorbent Assay ; ELISA ; Fluorescence ; Fluorescent Dyes ; Fluorescence Agents ; Fluorescent Agents ; fluorescent dye/probe ; Genetic Engineering ; Genetic Engineering Biotechnology ; Genetic Engineering Molecular Biology ; Recombinant DNA Technology ; genetically engineered ; Goals ; Cyclic GMP ; Guanosine Cyclic Monophosphate ; cGMP ; Half-Life ; Human ; Modern Man ; Immunotherapy ; Immune mediated therapy ; Immunologically Directed Therapy ; immune therapeutic approach ; immune therapeutic interventions ; immune therapeutic regimens ; immune therapeutic strategy ; immune therapy ; immune-based therapies ; immune-based treatments ; immuno therapy ; Infection ; Inflammation ; intravenous injection ; Joints ; Lead ; Pb element ; heavy metal Pb ; heavy metal lead ; Ligands ; Lung ; Lung Respiratory System ; pulmonary ; macrophage ; MÏ ; Microbiology ; Mus ; Mice ; Mice Mammals ; Murine ; neutrophil ; Blood Neutrophil ; Blood Polymorphonuclear Neutrophil ; Marrow Neutrophil ; Neutrophilic Granulocyte ; Neutrophilic Leukocyte ; Polymorphonuclear Cell ; Polymorphonuclear Leukocytes ; Polymorphonuclear Neutrophils ; Organism ; living system ; Patients ; Peptides ; Drug Kinetics ; Pharmacokinetics ; Pichia ; Hansenula ; Probability ; Production ; Proteins ; Pseudomonas aeruginosa ; P aeruginosa ; P. aeruginosa ; Pseudomonas pyocyanea ; Request for Proposals ; Adult Respiratory Distress Syndrome ; ARDS ; Acute Respiratory Distress ; Acute Respiratory Distress Syndrome ; Adult ARDS ; Adult RDS ; Da Nang Lung ; Shock Lung ; Stiff lung ; wet lung ; Rights ; RNA Splicing ; Splicing ; Rodent ; Rodentia ; Rodents Mammals ; Role ; social role ; Salmonella ; Computer software ; Software ; Staphylococcus aureus ; S aureus ; S. aureus ; Staph aureus ; Tail ; Technology ; Testing ; Time ; Toxicology ; Toxin ; Work ; cytokine ; Intensive Care ; Cavia ; Guinea Pigs ; Guinea Pigs Mammals ; base ; Organ ; Label ; improved ; Surface ; Phase ; Variant ; Variation ; Biological ; Superantigens ; Chemicals ; Inflammation Mediators ; inflammatory mediator ; Funding ; Immunological response ; host response ; immune system response ; immunoresponse ; Immune response ; Therapeutic ; Inflammatory ; Knowledge ; Scientist ; Complex ; System ; American ; Receptor Protein ; receptor ; young animal ; juvenile animal ; Animal Models and Related Studies ; model of animal ; model organism ; Animal Model ; Structure ; Pharmacodynamics ; Modeling ; response ; Myeloid Cells ; Molecular Interaction ; Binding ; preventing ; prevent ; Homolog of Drosophila TOLL ; TLR4 ; Toll Homologue ; toll-like receptor 4 ; TLR4 gene ; Dose ; Data ; Molecular Analysis ; Receptor Activation ; Recombinants ; in vivo ; Ligand Binding ; Non-Rodent Model ; Small Business Innovation Research Grant ; SBIR ; Small Business Innovation Research ; Preparation ; Characteristics ; Molecular ; Process ; Pathway interactions ; pathway ; pre-clinical ; preclinical ; Sepsis ; blood infection ; bloodstream infection ; older patient ; elderly patient ; Treatment Efficacy ; intervention efficacy ; therapeutic efficacy ; therapy efficacy ; manufacturing process ; pathogenic bacteria ; bacteria pathogen ; bacterial pathogen ; aged ; innovation ; innovate ; innovative ; novel therapeutics ; new drug treatments ; new drugs ; new therapeutics ; new therapy ; next generation therapeutics ; novel drug treatments ; novel drugs ; novel therapy ; FDA approved ; effective therapy ; effective treatment ; cGMP production ; stability testing ; Regimen ; Medical emergency ; Formulation ; preclinical trial ; pre-clinical trial ; experimental study ; experiment ; experimental research ; efficacy study ; cytokine release syndrome ; cytokine storm ; cecal ligation puncture ; CLP model ; CLP mouse model ; Cecal ligation perforation ; pharmacokinetics and pharmacodynamics ; PK/PD ; systemic inflammatory response ; systemic inflammation ; COVID-19 mortality ; COVID-19 associated death ; COVID-19 associated fatality ; COVID-19 associated mortality ; COVID-19 death ; COVID-19 fatality ; COVID-19 induced death ; COVID-19 induced fatality ; COVID-19 induced mortality ; COVID-19 related death ; COVID-19 related fatality ; COVID-19 related mortality ; COVID19 associated death ; COVID19 associated fatality ; COVID19 associated mortality ; COVID19 death ; COVID19 fatality ; COVID19 induced death ; COVID19 induced fatality ; COVID19 induced mortality ; COVID19 mortality ; COVID19 related death ; COVID19 related fatality ; COVID19 related mortality ; SARS-CoV-2 associated death ; SARS-CoV-2 associated fatality ; SARS-CoV-2 associated mortality ; SARS-CoV-2 death ; SARS-CoV-2 fatality ; SARS-CoV-2 induced death ; SARS-CoV-2 induced fatality ; SARS-CoV-2 induced mortality ; SARS-CoV-2 mortality ; SARS-CoV-2 related death ; SARS-CoV-2 related fatality ; SARS-CoV-2 related mortality ; coronavirus disease 2019 associated death ; coronavirus disease 2019 associated fatality ; coronavirus disease 2019 associated mortality ; coronavirus disease 2019 death ; coronavirus disease 2019 fatality ; coronavirus disease 2019 induced death ; coronavirus disease 2019 induced fatality ; coronavirus disease 2019 induced mortality ; coronavirus disease 2019 mortality ; coronavirus disease 2019 related death ; coronavirus disease 2019 related fatality ; coronavirus disease 2019 related mortality ; death due to COVID-19 ; death due to COVID19 ; death due to SARS-CoV-2 ; death due to coronavirus disease 2019 ; death due to severe acute respiratory syndrome coronavirus 2 ; death in COVID ; death in COVID-19 ; death in SARS-CoV-2 ; death in coronavirus disease ; death in coronavirus disease 2019 ; death in severe acute respiratory syndrome coronavirus 2 ; fatality due to COVID-19 ; fatality due to COVID19 ; fatality due to SARS-CoV-2 ; fatality due to coronavirus disease 2019 ; fatality due to severe acute respiratory syndrome coronavirus 2 ; mortality due to COVID-19 ; mortality due to COVID19 ; mortality due to SARS-CoV-2 ; mortality due to coronavirus disease 2019 ; mortality due to severe acute respiratory syndrome coronavirus 2 ; severe acute respiratory syndrome coronavirus 2 associated death ; severe acute respiratory syndrome coronavirus 2 associated fatality ; severe acute respiratory syndrome coronavirus 2 associated mortality ; severe acute respiratory syndrome coronavirus 2 death ; severe acute respiratory syndrome coronavirus 2 fatality ; severe acute respiratory syndrome coronavirus 2 induced death ; severe acute respiratory syndrome coronavirus 2 induced fatality ; severe acute respiratory syndrome coronavirus 2 induced mortality ; severe acute respiratory syndrome coronavirus 2 mortality ; severe acute respiratory syndrome coronavirus 2 related death ; severe acute respiratory syndrome coronavirus 2 related fatality ; severe acute respiratory syndrome coronavirus 2 related mortality ;
